咪喹莫特乳膏联合重组人干扰素α-2b在尖锐湿疣治疗中的可行性及安全性  

Feasibility and Safety of Imiquimod Cream Combined with recombinant Human Interferon α-2b in the Treatment of Condyloma Acuminatum

作　　者：韩芸 张娟 李萍 HAN Yun;ZHANG Juan;LI Ping(Department of Dermatology, The Fourth People’s Hospital of Qinghai Province, Xining 810000, China;Outpatient Department, The Fourth Peopled Hospital of Qinghai Province, Xining 810000, China;Physical Examination Center, The Fourth Peopled Hospital of Qinghai Province, Xining 810000, China)

机构地区：[1]青海省第四人民医院皮肤科,西宁810000 [2]青海省第四人民医院门诊部,西宁810000 [3]青海省第四人民医院体检中心,西宁810000

出　　处：《长春中医药大学学报》2019年第5期939-941,共3页Journal of Changchun University of Chinese Medicine

基　　金：青海省科技厅(局)科技项目(2014-k-16)

摘　　要：目的探讨咪喹莫特乳膏联合重组人干扰素α-2b在尖锐湿疣治疗中的可行性及安全性。方法以我院2017年8月-2018年8月收治的160例尖锐湿疣患者为研究对象,根据随机数字表法将受试者进行分组,其中对照组80例仅接受咪喹莫特乳膏治疗,研究组80例在对照组的基础上联合重组人干扰素α-2b治疗,比较2组的治疗总有效率、治疗前后各免疫功能指标、用药安全性及复发情况。结果研究组治疗总有效率显著高于对照组(P <0.05);治疗后2组CD8^+显著降低,CD3^+、CD4^+、CD4^+/CD8^+显著升高,且研究组显著优于对照组(P <0.05);治疗后随访6个月,研究组复发率显著低于对照组(P <0.05)。结论咪喹莫特乳膏联合重组人干扰素α-2b可有效改善患者的免疫功能,降低复发率,疗效安全显著,值得在尖锐湿疣治疗中应用推广。Objective To explore feasibility and safety of imiquimod cream combined with recombinant human interferon α-2b in the treatment of condyloma acuminatum. Methods 160 cases with condyloma acuminatum were selected as research object from August 2017 to August 2018, the subjects were randomly divided into control group and study group, and each group of 80 cases. The control group was receive imiquimod cream treatment, the study group on the basis of this was given recombinant human interferon α-2 b treatment. Total effective rate of treatment, immune function indicators before and after treatment, medication safety and recurrence were compared between the two groups. Results The total effective rate of treatment in the study group was significantly higher than that in the control group(P < 0.05), the CD8^+ in the two groups was significantly decreased and the CD3^+, CD4^+, CD4^+/CD8^+ was significantly increased after treatment, and the study group was significantly better than the control group(P < 0.05). The recurrence rate in the study group was significantly lower than that in the control group after 6 months of follow-up(P < 0.05). Conclusion Imiquimod cream combined with recombinant human interferon α-2b can effectively improve the immune function of patients, reduce the recurrence rate, and has a safe and effective effect worthy of application in the treatment of condyloma acuminata.

关 键 词：咪喹莫特乳膏 重组人干扰素Α-2B 尖锐湿疣 免疫功能 复发率 

分 类 号：R759[医药卫生—皮肤病学与性病学]